» Articles » PMID: 36013561

Chronic Thromboembolic Pulmonary Hypertension: An Observational Study

Abstract

Background and Objectives: Chronic thromboembolic pulmonary hypertension (CTEPH) has a high mortality. The treatment of CTEPH could be balloon pulmonary angioplasty (BPA), medical (MT) or pulmonary endarterectomy (PEA). This study aims to assess the clinical characteristics of CTEPH patients, surgically or medically treated, in a pulmonology referral center. Materials and Methods: A total of 124 patients with PH with suspected CTEPH (53 male subjects and 71 female subjects; mean age at diagnosis 67 ± 6) were asked to give informed consent and then were evaluated. The presence of CTEPH was ascertained by medical evaluations, radiology and laboratory tests. Results: After the evaluation of all clinical data, 65 patients met the inclusion criteria for CTEPH and they were therefore enrolled (22 males and 43 females; mean age at diagnosis was 69 ± 8). 26 CTEPH patients were treated with PEA, 32 with MT and 7 with BPA. There was a statistically significant age difference between the PEA and MT groups, at the time of diagnosis, the PEA patients were younger than the MT patients, whereas there was no statistically significant difference in other clinical characteristics (e.g., smoking habit, thrombophilia predisposition), as well as functional and hemodynamic parameters (e.g., 6-min walk test, right heart catheterization). During three years of follow-up, no patients in the PEA groups died; conversely, eleven patients in the MT group died during the same period (p < 0.05). Furthermore, a significant decrease in plasma BNP values and an increase in a meter at the six-minute walk test, 1 and 3 years after surgery, were observed in the PEA group (p < 0.05). Conclusions: This study seems to confirm that pulmonary endarterectomy (PEA) can provide an improvement in functional tests in CTEPH.

Citing Articles

Development and Validation of a Nomogram for Balloon Pulmonary Angioplasty-Related Complications in Patients with Chronic Thromboembolic Pulmonary Hypertension.

Li X, Zhang Y, Jin Q, Luo Q, Zhao Q, Yang T Rev Cardiovasc Med. 2024; 24(3):72.

PMID: 39077502 PMC: 11263984. DOI: 10.31083/j.rcm2403072.


Bibliometric analysis of T-cells immunity in pulmonary hypertension from 1992 to 2022.

Chen X, Yan Z, Pan Q, Zhang C, Chen Y, Liang X Immun Inflamm Dis. 2024; 12(7):e1280.

PMID: 38967362 PMC: 11225084. DOI: 10.1002/iid3.1280.


Notch ratio in pulmonary flow predicts long-term survival after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension.

Beijk M, Winkelman J, Eckmann H, Samson D, Widyanti A, Vleugels J Heart Vessels. 2024; 39(11):968-978.

PMID: 38837085 PMC: 11489231. DOI: 10.1007/s00380-024-02422-5.


Sildenafil improves hemodynamic changes caused by acute pulmonary embolism by inhibiting Rho kinase activity.

Wang H, Li W, Yan Y, Shi M, Hou F, Zhang R J Int Med Res. 2024; 52(4):3000605241240938.

PMID: 38603613 PMC: 11010764. DOI: 10.1177/03000605241240938.


Evaluating the efficacy of balloon pulmonary angioplasty using quantitative analysis of SPECT pulmonary ventilation/perfusion scintigraphy in patients with chronic thromboembolic pulmonary hypertension.

Ma R, Jin C, Yang S, Han P, Li H, Liu J Quant Imaging Med Surg. 2024; 14(3):2590-2602.

PMID: 38545067 PMC: 10963846. DOI: 10.21037/qims-23-1208.


References
1.
Ruaro B, Salton F, Baratella E, Confalonieri P, Geri P, Pozzan R . An Overview of Different Techniques for Improving the Treatment of Pulmonary Hypertension Secondary in Systemic Sclerosis Patients. Diagnostics (Basel). 2022; 12(3). PMC: 8947575. DOI: 10.3390/diagnostics12030616. View

2.
Sandqvist A, Kylhammar D, Bartfay S, Hesselstrand R, Hjalmarsson C, Kavianipour M . Risk stratification in chronic thromboembolic pulmonary hypertension predicts survival. Scand Cardiovasc J. 2020; 55(1):43-49. DOI: 10.1080/14017431.2020.1783456. View

3.
Wiedenroth C, Bandorski D, Ariobi K, Ghofrani H, Lankeit M, Liebetrau C . Does Age Matter? Pulmonary Endarterectomy in the Elderly Patient with CTEPH. Thorac Cardiovasc Surg. 2022; 70(8):663-670. DOI: 10.1055/s-0041-1740559. View

4.
Bonderman D, Turecek P, Jakowitsch J, Weltermann A, Adlbrecht C, Schneider B . High prevalence of elevated clotting factor VIII in chronic thromboembolic pulmonary hypertension. Thromb Haemost. 2003; 90(3):372-6. DOI: 10.1160/TH03-02-0067. View

5.
Puebla-Aldama D, Cueto-Robledo G, Barragan-Martinez M, Roldan-Valadez E, Navarro-Vergara D, Garcia-Cesar M . Review of Functional Status and Hemodynamic Parameters in Patients Diagnosed with Chronic Thromboembolic Pulmonary Hypertension (CTEPH) With and Without Antiphospholipid Syndrome (APLS). Curr Probl Cardiol. 2022; 48(7):101154. DOI: 10.1016/j.cpcardiol.2022.101154. View